Assessing Cancer Risk on Novel 29 MHz Micro-Ultrasound Images of the Prostate: Creation of the Micro-Ultrasound Protocol for Prostate Risk Identification

Sangeet Ghai, Gregg Eure, Vincent Fradet, Matthew E. Hyndman, Theresa McGrath, Brian Wodlinger, Christian Pavlovich

Research output: Contribution to journalArticle

Abstract

Purpose: Conventional ultrasound systems operate at 6 to 9 MHz and serve as the standard of care to guide prostate biopsies. We present a protocol using a novel high resolution (29 MHz) transrectal prostate micro-ultrasound system. This protocol includes a scoring system to assess the risk of prostatic carcinoma and enable real-time targeted biopsies. Materials and Methods: The ExactVu™ system is currently being used in a multisite, 2,000-patient, randomized clinical trial. Cine loops of 400 biopsies from this trial were used to create the PRI-MUS™ (prostate risk identification using micro-ultrasound) protocol and risk scale. Validation was performed in an independent, pathology blinded set of 100 cines. Three of the 5 investigators performing this validation were familiar with micro-ultrasound but naïve to the PRI-MUS protocol and they received only 1 hour of training. Results: Each increase in risk score demonstrated a 10.1% increase (95% CI 9.3-10.8) in the probability of clinically significant cancer. The risk score also increased with Gleason sum and cancer length with a slope of 0.15 (95% CI 0.09-0.21) and 0.58 (95% CI 0.43-0.73), respectively. Sensitivity and specificity were 80% and 37%, respectively, and the mean ± SD ROC AUC was 60% ± 2%. The protocol was more accurate for detecting high grade disease (Gleason sum greater than 7) with a peak AUC of 74% (mean 66%). Conclusions: The new resolution of the micro-ultrasound platform paired with the PRI-MUS protocol shows promise for real-time visualization of suspicious lesions and targeting of biopsies. The improved performance of the protocol in more significant disease is consistent with the focus of the field on decreasing insignificant diagnoses and detecting high risk disease early.

Original languageEnglish (US)
JournalJournal of Urology
DOIs
StateAccepted/In press - 2016

Fingerprint

Prostate
Neoplasms
Biopsy
Area Under Curve
Standard of Care
Randomized Controlled Trials
Research Personnel
Pathology
Carcinoma
Sensitivity and Specificity

Keywords

  • Biopsy
  • Clinical protocols
  • Diagnostic imaging
  • Prostatic neoplasms
  • Ultrasonography

ASJC Scopus subject areas

  • Urology

Cite this

Assessing Cancer Risk on Novel 29 MHz Micro-Ultrasound Images of the Prostate : Creation of the Micro-Ultrasound Protocol for Prostate Risk Identification. / Ghai, Sangeet; Eure, Gregg; Fradet, Vincent; Hyndman, Matthew E.; McGrath, Theresa; Wodlinger, Brian; Pavlovich, Christian.

In: Journal of Urology, 2016.

Research output: Contribution to journalArticle

@article{56d607cc642c41e9aebf465bea5f8fc5,
title = "Assessing Cancer Risk on Novel 29 MHz Micro-Ultrasound Images of the Prostate: Creation of the Micro-Ultrasound Protocol for Prostate Risk Identification",
abstract = "Purpose: Conventional ultrasound systems operate at 6 to 9 MHz and serve as the standard of care to guide prostate biopsies. We present a protocol using a novel high resolution (29 MHz) transrectal prostate micro-ultrasound system. This protocol includes a scoring system to assess the risk of prostatic carcinoma and enable real-time targeted biopsies. Materials and Methods: The ExactVu™ system is currently being used in a multisite, 2,000-patient, randomized clinical trial. Cine loops of 400 biopsies from this trial were used to create the PRI-MUS™ (prostate risk identification using micro-ultrasound) protocol and risk scale. Validation was performed in an independent, pathology blinded set of 100 cines. Three of the 5 investigators performing this validation were familiar with micro-ultrasound but na{\"i}ve to the PRI-MUS protocol and they received only 1 hour of training. Results: Each increase in risk score demonstrated a 10.1{\%} increase (95{\%} CI 9.3-10.8) in the probability of clinically significant cancer. The risk score also increased with Gleason sum and cancer length with a slope of 0.15 (95{\%} CI 0.09-0.21) and 0.58 (95{\%} CI 0.43-0.73), respectively. Sensitivity and specificity were 80{\%} and 37{\%}, respectively, and the mean ± SD ROC AUC was 60{\%} ± 2{\%}. The protocol was more accurate for detecting high grade disease (Gleason sum greater than 7) with a peak AUC of 74{\%} (mean 66{\%}). Conclusions: The new resolution of the micro-ultrasound platform paired with the PRI-MUS protocol shows promise for real-time visualization of suspicious lesions and targeting of biopsies. The improved performance of the protocol in more significant disease is consistent with the focus of the field on decreasing insignificant diagnoses and detecting high risk disease early.",
keywords = "Biopsy, Clinical protocols, Diagnostic imaging, Prostatic neoplasms, Ultrasonography",
author = "Sangeet Ghai and Gregg Eure and Vincent Fradet and Hyndman, {Matthew E.} and Theresa McGrath and Brian Wodlinger and Christian Pavlovich",
year = "2016",
doi = "10.1016/j.juro.2015.12.093",
language = "English (US)",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Assessing Cancer Risk on Novel 29 MHz Micro-Ultrasound Images of the Prostate

T2 - Creation of the Micro-Ultrasound Protocol for Prostate Risk Identification

AU - Ghai, Sangeet

AU - Eure, Gregg

AU - Fradet, Vincent

AU - Hyndman, Matthew E.

AU - McGrath, Theresa

AU - Wodlinger, Brian

AU - Pavlovich, Christian

PY - 2016

Y1 - 2016

N2 - Purpose: Conventional ultrasound systems operate at 6 to 9 MHz and serve as the standard of care to guide prostate biopsies. We present a protocol using a novel high resolution (29 MHz) transrectal prostate micro-ultrasound system. This protocol includes a scoring system to assess the risk of prostatic carcinoma and enable real-time targeted biopsies. Materials and Methods: The ExactVu™ system is currently being used in a multisite, 2,000-patient, randomized clinical trial. Cine loops of 400 biopsies from this trial were used to create the PRI-MUS™ (prostate risk identification using micro-ultrasound) protocol and risk scale. Validation was performed in an independent, pathology blinded set of 100 cines. Three of the 5 investigators performing this validation were familiar with micro-ultrasound but naïve to the PRI-MUS protocol and they received only 1 hour of training. Results: Each increase in risk score demonstrated a 10.1% increase (95% CI 9.3-10.8) in the probability of clinically significant cancer. The risk score also increased with Gleason sum and cancer length with a slope of 0.15 (95% CI 0.09-0.21) and 0.58 (95% CI 0.43-0.73), respectively. Sensitivity and specificity were 80% and 37%, respectively, and the mean ± SD ROC AUC was 60% ± 2%. The protocol was more accurate for detecting high grade disease (Gleason sum greater than 7) with a peak AUC of 74% (mean 66%). Conclusions: The new resolution of the micro-ultrasound platform paired with the PRI-MUS protocol shows promise for real-time visualization of suspicious lesions and targeting of biopsies. The improved performance of the protocol in more significant disease is consistent with the focus of the field on decreasing insignificant diagnoses and detecting high risk disease early.

AB - Purpose: Conventional ultrasound systems operate at 6 to 9 MHz and serve as the standard of care to guide prostate biopsies. We present a protocol using a novel high resolution (29 MHz) transrectal prostate micro-ultrasound system. This protocol includes a scoring system to assess the risk of prostatic carcinoma and enable real-time targeted biopsies. Materials and Methods: The ExactVu™ system is currently being used in a multisite, 2,000-patient, randomized clinical trial. Cine loops of 400 biopsies from this trial were used to create the PRI-MUS™ (prostate risk identification using micro-ultrasound) protocol and risk scale. Validation was performed in an independent, pathology blinded set of 100 cines. Three of the 5 investigators performing this validation were familiar with micro-ultrasound but naïve to the PRI-MUS protocol and they received only 1 hour of training. Results: Each increase in risk score demonstrated a 10.1% increase (95% CI 9.3-10.8) in the probability of clinically significant cancer. The risk score also increased with Gleason sum and cancer length with a slope of 0.15 (95% CI 0.09-0.21) and 0.58 (95% CI 0.43-0.73), respectively. Sensitivity and specificity were 80% and 37%, respectively, and the mean ± SD ROC AUC was 60% ± 2%. The protocol was more accurate for detecting high grade disease (Gleason sum greater than 7) with a peak AUC of 74% (mean 66%). Conclusions: The new resolution of the micro-ultrasound platform paired with the PRI-MUS protocol shows promise for real-time visualization of suspicious lesions and targeting of biopsies. The improved performance of the protocol in more significant disease is consistent with the focus of the field on decreasing insignificant diagnoses and detecting high risk disease early.

KW - Biopsy

KW - Clinical protocols

KW - Diagnostic imaging

KW - Prostatic neoplasms

KW - Ultrasonography

UR - http://www.scopus.com/inward/record.url?scp=84977515207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977515207&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2015.12.093

DO - 10.1016/j.juro.2015.12.093

M3 - Article

C2 - 26791931

AN - SCOPUS:84977515207

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

ER -